Takeda: Primary Endpoint Not Achieved In Orteronel Phase III Trials
This article was originally published in PharmAsia News
Executive Summary
Japan’s Takeda announced on July 26 that the primary endpoint in Phase III trials with their non-steroid androgen inhibitor orteronel was not achieved.